Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis.

Medicine (Baltimore) · 2019 · PMC6824777 · PMID 31651902

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

The data in Figure 5 B shows that there is a clear trend of decreasing grade 3 or greater AEs in NSCLC patients with the T790M mutation.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.